Codexis, Inc. (CDXS)

1,6100 +0,0600 (+3,87%) Al 09:55AM EDT. Mercato aperto.

Codexis, Inc.

200 Penobscot Drive
Redwood City, CA 94063
United States
650 421 8100
https://www.codexis.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 248

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Stephen George Dilly MBBS, Ph.D.	Pres, CEO & Director	753,61k	N/D	1960
Mr. Kevin Norrett M.B.A., M.S.	Chief Operating Officer	507,28k	N/D	1973
Ms. Margaret Fitzgerald J.D.	Chief Legal and Compliance Officer, Gen. Counsel & Sec.	300,03k	N/D	1971
Mr. Sriram Ryali M.B.A.	Chief Financial Officer	N/D	N/D	1982
Carrie McKim	Director of Investor Relations	N/D	N/D	N/D
Ms. Karen Frechou-Armijo	Sr. VP & Head of HR	N/D	N/D	N/D
Dr. Stefan Lutz Ph.D.	Sr. VP of Research	N/D	N/D	N/D
Mr. Robert Sato M.B.A., Ph.D.	Sr. VP of Pharmaceutical Devel., Quality & Regulatory	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Governance aziendale

L'ISS Governance QualityScore di Codexis, Inc. al 1 settembre 2023 è 5. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 2; diritti degli azionisti: 7; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.